Skip to main content
. 2017 Dec 13;33(6):923–934. doi: 10.1093/ndt/gfx304

FIGURE 9.

FIGURE 9

Platelet aggregation in GPx3−/− in the setting of chronic kidney injury. (A) OD of washed platelets derived from WT + sham versus GPx3−/− + sham following treatment with 1 μM ADMA (0.70 ± 0.06) (n = 6 animals) versus (0.62 ± 0.05) (n = 6 animals) (*P = 0.028) and 10 μM ADMA (0.57 ± 0.04) (n = 6 animals) versus (0.47 ± 0.04) (n = 6 animals) (**P = 0.004). (B) OD after treatment with vehicle, WT + CKD (1.10 ± 0.04) (n = 6 animals) versus GPx3−/−+  CKD (0.63 ± 0.05) mice (*P < 0.001), GPx3−/− + CKD + vehicle versus GPx3−/− + CKD + ebselen (0.84 ± 0.03) mice (**P < 0.001) after 0.1 μM ADP; WT + CKD (0.89 ± 0.03) (n = 7 animals) versus GPx3−/− + CKD (0.52 ± 0.03) mice (***P < 0.001), GPx3−/− + CKD + vehicle versus GPx3−/− + CKD + ebselen (0.70 ± 0.03) mice (†P < 0.001) after 10 μM ADP, WT + CKD (0.73 ± 0.05) (n = 7 animals) versus GPx3−/− + CKD + vehicle (0.48 ± 0.03) mice (††P < 0.001), GPx3−/− + CKD + vehicle versus GPx3−/− + CKD + ebselen (0.67 ± 0.03) mice (^P < 0.001) and after 100 μM ADP WT + CKD (0.57 ± 0.03) (n = 7 animals) versus GPx3−/− + CKD + vehicle (0.39 ± 0.07) (†††P < 0.001), GPx3−/− + CKD + vehicle versus GPx3−/− + CKD + ebselen (0.65 ± 0.02) (^^P < 0.001).